Predictors of disease aggressiveness influence outcome from immunotherapy treatment in renal clear cell carcinoma

Abstract

Renal clear cell carcinoma (RCC) is the most common type of kidney cancer and has a high propensity for metastasis. While treatment with immune checkpoint inhibitors, such as anti-PD-1, have shown modest improvements in survival for RCC, it is difficult to identify responders from non-responders. Attempts to elucidate the mechanisms associated with differential response to checkpoint inhibitors have been limited by small sample size making it difficult to detect meaningful associations. We utilized existing large datasets from The Cancer Genome Atlas (TCGA) to first find predictors of disease aggressiveness in the tumor microenvironment (TME) and hypothesized that these same predictors may influence response to immunotherapy. We found primary metastatic (M1-stage IV) tumors exhibit high immune infiltration, and high TP53-inactivation induced senescence activity compared to nonmetastatic (M0-Stage I/II) tumors. Moreover, some TME features inferred from deconvolution algorithms, which differ between M0 and M1 tumors, also influence overall survival. A focused analysis identified interactions between tumor TP53-inactivation induced senescence activity and expression of inflammatory molecules in pre-treatment RCC tumors, which predict both change in tumor size and response to checkpoint blockade therapy. We also noted frequency of inactivating mutations in the protein polybromo-1 (PBRM1) gene was found to be negatively associated with TP53-inactivation induced senescence enrichment. Our findings suggest a mechanism by which tumor TP53-inactivation induced senescence can modulate the TME and thereby influence outcome from checkpoint blockade therapy.

Multi‐omics analysis of tumor mutation burden combined with immune infiltrates in bladder urothelial carcinoma

“…Nowadays, immunotherapy has become an effective treatment method for advanced or metastatic cancers (Aoun, Rassy, Assi, Albisinni, & Katan, 2017;Hoos, 2016;Kamal, Cheng, Frost, & Amos, 2019). Mainly immunotherapy categories include monoclonal antibody immune checkpoint inhibitors (ICIs), therapeutic antibody, cancer vaccines, immune system modulators, cell therapy, and small synthetic molecule inhibitors.…”

Identification of a Metastasis-Associated Gene Signature of Clear Cell Renal Cell Carcinoma

“…Immunotherapy has recently been identified as an effective methodology for advanced or aggressive cancers (Hoos, 2016 ; Aoun et al, 2017 ; Kamal et al, 2018 ). In addition, many studies have found that the tumor mutation burden (TMB) and neoepitopes in many cancer types are closely associated with immunotherapy (Kandoth et al, 2013 ; Brown et al, 2014 ).…”

Exploration of the Associations of lncRNA Expression Patterns with Tumor Mutation Burden and Prognosis in Colon Cancer

“…Immunotherapy is rapidly attracting attention in cancerassociated treatment, because it has shown efficacy in some advanced and aggressive cancers. [4][5][6] At present, tumor-cell PD-L1 expression 7 and tumor-infiltrating lymphocytes 8 have been identified as biomarkers to assist in predicting the response of immunotherapy. However, not all patients show a good response to immunotherapy, with some having no response.…”